RECEPTOS INC (RCPT)
(Delayed Data from NSDQ)
$231.96 USD
-0.03 (-0.01%)
Updated Aug 27, 2015 03:59 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
[RCPT]
Reports for Purchase
Showing records 1 - 20 ( 82 total )
Industry: Medical - Drugs
Price: 10.00
Industry: Medical - Drugs
Downgrading Our Rating to NEUTRAL and Reducing Our Acquisition Value to $232 as Time Has Run Out for a Higher Bidder; Tender Offer Completed
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Drugs
August and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 100.00
Industry: Medical - Drugs
Q2 Financials: About $579 Million in Cash and Potential Acquisition on the Horizon; Reiterate OUTPERFORM and $348 Acquisition Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Drugs
Celgene Wants Receptos for $7.2 Billion, but We Anticipate Another Bidder is Possible; Reiterate OUTPERFORM and $348 Acquisition Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Drugs
July and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 100.00
Industry: Medical - Drugs
M-A Update: Recent Bids Caused Re-Evaluation of Our Valuation; Reiterate OUTPERFORM and Increasing Acquisition Value to $348.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Drugs
Emerging Pharmaceuticals - June and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 100.00
Industry: Medical - Drugs
Data from DDW Presentations Reduces Clinical Risk for Ozanimod Phase 3 in UC, in Our View; Reiterate OUTPERFORM and $211 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Drugs
Data from DDW Presentations Reduces Clinical Risk for Ozanimod Phase 3 in UC, in Our View; Reiterate OUTPERFORM and $211 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Drugs
Week Ahead in Life Sciences - Upcoming Events for the Week of May 18th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 10.00
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 11th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 10.00
Industry: Medical - Drugs
Financials: Cash Into 2018, Best-in-Class Drug Candidates and Top Management
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Drugs
May and 2015 Emerging Pharmaceuticals Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 50.00
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 27th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Drugs
Spectacular Ozanimod Phase 2 Data for Ulcerative Colitis Shown to be Durable Through 36 Weeks; Reiterate OUTPERFORM and $201 Acquisition Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 13th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 10.00
Industry: Medical - Drugs
April and 2015 Emerging Pharmaceuticals CatalystsThis report contains brief updates on the following: BIOD, BMRN, ICPT, LXRX, OMER, RCPT, RLYP, SGMO, VTAE, XOMA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 100.00
Industry: Medical - Drugs
April and 2015 Emerging Pharmaceuticals Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 100.00
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 23rd
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 10.00